| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
ST. LOUIS—Sigma-Aldrich Corp. announced at the end of December that it had acquired all outstanding shares of Cerilliant Corp. of Round Rock, Texas—a move purposefully designed to strengthen Sigma's analytical chemistry product portfolio and, as the company says, "to continue to deliver on its strategic growth plans." Specific terms of the deal were not disclosed, but Sigma says it expects this acquisition to be neutral to mildly accretive to earnings per share in 2011.

Sigma-Adrich calls Cerilliant a leading supplier of high-quality reference standards and materials that provides products that support the clinical diagnostics, environmental, nutraceutical, pharmaceutical, forensic and clinical toxicology markets. Cerilliant has been a portfolio company of Argenta Partners of Dallas, Texas for the past 10 years.

The 65-person Cerilliant brings to Sigma-Aldrich more than 2,800 products and more than 30 years of expertise in the design, development, synthesis, characterization and packaging of analytical standards, calibrators, controls and certified reference materials that are used in a wide range of analytical applications. Sigma notes that the standards company is well known for its "visionary approach" to serving these growing industries with a continually expanding line of innovative new products and sustains a modern, robust quality system incorporating cGMP, GLP and ISO requirements.

"Cerilliant's strong product suite and solid relationships with customers and analytical equipment suppliers will bring important new business opportunities to our Company's analytical arena," says Russel Gant, vice president of the analytical research business at Sigma-Aldrich. "Their experienced team and capabilities, combined with the quality and breadth of our current analytical brands, our broad scientific knowledge and our powerful global footprint will provide analytical customers around the globe with access to a broad and ever-increasing range of specialized, high-quality analytical standards from a convenient and reliable single source."

Sherri Pogue, president of Cerilliant and newly appointed director of the Round Rock site, adds, "Being part of the Sigma-Aldrich family will provide Cerilliant with the depth and breadth of resources that will allow us to continue to expand our development and offering of innovative products to support our customers' ever-evolving analytical requirements. We remain committed to providing our customers with unsurpassed quality and service."
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue